Alexion Pharmaceuticals’ stock soared Thursday as it reported higher-than-expected first quarter earnings and promising results from a study of its replacement for the company’s flagship drug Soliris.

On Wednesday, Xencor Inc. XNCR said it is revising its revenue outlook for royalties tied to Ultomiris. The company announced that its licensee, Alexion Pharmaceuticals, Inc., has stated it does not ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs and ...

Alexion Pharmaceuticals Inc. has won approval from its board of directors for a two-for-one stock split, which if approved would double the number of issued common stock shares from 145 million to 290 ...

Alexion Pharmaceuticals will pay a huge premium to buy Synageva BioPharma in an $8.4-billion deal for a rare disease treatment maker that lost nearly $60 million in the first quarter and has no ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Monopar Therapeutics, Inc. (NASDAQ:MNPR) shares are trading lower Friday after gaining on Thursday. The stock was volatile yesterday following the company’s agreement with Alexion, AstraZeneca Rare ...